Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Radius Raises $91 Million, Moves Toward Public Listing

This article was originally published in Start Up

Executive Summary

Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.

Related Content

After Canceling IPO, Radius May Tap Institutional Investors
Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round
Wellcome Trust Launches £200 Million Fund For Diverse Health Care Investments
Shire Nabs Advanced BioHealing Before It Can Test the Public Waters
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
MPM/Novartis Fund Deals with Radius
MPM/Novartis Fund Deals with Radius


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts